A patient with type 1 diabetes reports mixing NPH and regular insulin to allow for one injection. The nurse knows:

Choice A reason: Drugs with a narrow therapeutic range, like digoxin, require plasma level monitoring to ensure concentrations remain within a safe and effective range. This prevents toxicity (e.g., arrhythmias) or subtherapeutic effects, as small dose changes can significantly alter blood levels, making monitoring critical for patient safety and efficacy.

Choice B reason: Intravenous administration does not inherently address the risks of a narrow therapeutic range. While it ensures rapid delivery, it increases toxicity risk due to immediate bioavailability. Monitoring plasma levels is more critical than the route to maintain safe and effective drug concentrations, making this choice less appropriate.

Choice C reason: Administering at intervals longer than the half-life may lead to subtherapeutic levels for drugs with a narrow therapeutic range, reducing efficacy. Consistent dosing and plasma level monitoring are needed to maintain steady-state concentrations within the therapeutic window, making this choice incorrect for managing such drugs.

Choice D reason: Teaching that maximum effects occur quickly is inaccurate for most narrow therapeutic range drugs, which often require steady-state concentrations over time. Without monitoring, toxicity or inefficacy risks increase. Patient education should focus on adherence and monitoring, not rapid effects, making this choice inappropriate.

Choice A reason: Dry cough is a common, not serious, side effect of ACE inhibitors due to bradykinin accumulation. While bothersome, it’s not life-threatening like angioedema. It often necessitates switching to an ARB, but calling it serious overstates the risk, making this choice incorrect.

Choice B reason: Dry cough occurs in 5-20% of ACE inhibitor users but doesn’t typically subside with continued use, as bradykinin accumulation persists. Patients often require a medication change (e.g., to ARBs), making the claim that it will subside over time inaccurate and incorrect.

Choice C reason: Dry cough is common but not universal in ACE inhibitor users, affecting 5-20% of patients due to variable bradykinin sensitivity. Stating it occurs in all patients is inaccurate, as many tolerate ACE inhibitors without cough, making this choice incorrect.

Choice D reason: Dry cough, caused by bradykinin buildup, affects some ACE inhibitor users and is uncomfortable, often requiring a switch to an ARB, which doesn’t affect bradykinin. This accurately reflects the side effect’s impact and management, making it the correct choice for the nurse’s response.